# Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments

> **NCT00688675** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2912 (estimated)

## Conditions studied

- GERD

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00688675
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 2912 (ESTIMATED)
- **Last updated:** 2010-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688675, "Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00688675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*